Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | OXTR | P30559 | 1/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238887 | 0.93 | SIGMAR1 (0.54) | SIGMAR1HTR2BFGFR1SRC | |
| SCHEMBL239568 | 0.89 | SIGMAR1 (0.50) | SIGMAR1MEN1KMT2ALTA4H | |
| SCHEMBL238657 | 0.88 | SIGMAR1 (0.51) | SIGMAR1LTA4HADORA2AADORA1 | |
| SCHEMBL14058655 | 0.86 | SIGMAR1 (0.48) | SIGMAR1HTR2BNPC1RAB9AMEN1 | |
| SCHEMBL239116 | 0.83 | SIGMAR1 (0.69) | SIGMAR1NPC1KCNH2 | |
| Oxalic Acid SCHEMBL235363 | 0.80 | SIGMAR1 (0.62) | SIGMAR1HTR2BKCNH2 | |
| SCHEMBL31466386 | 0.78 | SIGMAR1 (0.78) | SIGMAR1HTR2BKCNH2 | |
| SCHEMBL13975168 | 0.76 | SIGMAR1 (0.61) | SIGMAR1HTR2BNPC1RAB9AMEN1 | |
| SCHEMBL238772 | 0.76 | RXFP1 (0.51) | SIGMAR1RAB9A | |
| SCHEMBL3839358 | 0.74 | MAPK1 (0.38) | NPC1RAB9AMEN1KMT2AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097394-B1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2013-12-25 | — | — | EP | claimed |
| US-8349878-B2 | 1,2,4-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-01-08 | — | — | US | claimed |
| US-20120004211-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-05 | — | — | US | claimed |
| US-8039497-B2 | 1,2,4-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-10-18 | — | — | US | claimed |
| US-20100004224-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-01-07 | — | — | US | claimed |
| EP-2097394-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-09 | — | — | EP | claimed |
| WO-2008055932-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-05-15 | — | — | WO | claimed |
| EP-1921073-A1 | 1,2,4-Triazole derivatives as sigma receptor inhibitors | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | claimed |
| EP-2531191-B1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | ESTEVE LABOR DR (ES) | 2016-03-30 | — | — | EP | disclosed |
| EP-2097394-B1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2013-12-25 | — | — | EP | disclosed |
| US-8349878-B2 | 1,2,4-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-01-08 | — | — | US | disclosed |
| EP-2531191-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-12-12 | — | — | EP | disclosed |
| US-20120004211-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-8039497-B2 | 1,2,4-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-10-18 | — | — | US | disclosed |
| WO-2011095584-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-11 | — | — | WO | disclosed |
| EP-2353598-A1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | disclosed |
| US-20100004224-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-01-07 | — | — | US | disclosed |
| EP-2097394-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008055932-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921073-A1 | 1,2,4-Triazole derivatives as sigma receptor inhibitors | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004224-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885HTR2B 30/4885NPC1 716/4885 |
| US-20120004211-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885HTR2B 34/4885NPC1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.